Your session is about to expire
← Back to Search
CSL312 for Idiopathic Pulmonary Fibrosis
Study Summary
This trial will assess if CSL312 is a safe and effective treatment for idiopathic pulmonary fibrosis.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 64 Patients • NCT04656418Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You are male or female and are 40 years of age or older.You have a problem with your heart's electrical signals or high blood pressure that is not under control.
- Group 1: CSL312
- Group 2: Placebo
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the geographical scope of this experiment?
"The present trial is accessible across 23 different sites, including Ocala, Los Angeles and Hannibal. It may be beneficial to pick the nearest location as it can reduce travelling expenses if you decide to join in on this experience."
Are there any vacancies available to join this clinical experiment?
"Clinicaltrials.gov indicates that recruitment for this trial is proceeding as planned, with the initial post dated January 27th 2022 and a recent update on November 29th 2022."
Is this a trailblazing clinical trial?
"Currently, CSL312 is being evaluated in two live studies across 19 countries and 52 cities. This drug was first trialled back in 2021 by CSL Behring with 171 participants as part of the Phase 3 approval process; since its inception, it has seen over 18 thousand trials."
Has CSL312 been confirmed to meet the regulatory criteria of the FDA?
"Based on our assessment, CSL312 is rated a 2 for safety due to the limited clinical data available that has only demonstrated its protective qualities."
How many individuals have been accepted into this experiment?
"Affirmative. According to clinicaltrials.gov, this particular medical trial is still recruiting patients who were first posted on January 27th of 2022 and recently updated on November 29th of the same year. The goal is to enlist 80 individuals from 23 separate sites."
Has CSL312 been tested for efficacy in other research endeavors?
"CSL312 was initially studied in 2021 at Queen Mary Hospital, University of Hong Kong. To date, over 18000 trials have been concluded and 2 studies are still active with one of the sites located in Ocala, Florida."
Who else is applying?
What portion of applicants met pre-screening criteria?
What site did they apply to?
How many prior treatments have patients received?
What state do they live in?
What questions have other patients asked about this trial?
Why did patients apply to this trial?
How responsive is this trial?
Average response time
- < 2 Days
Most responsive sites:
- Weill Cornell Medical Center: < 48 hours
Typically responds via
Share this study with friends
Copy Link
Messenger